Je Jong Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Je Jong Kim has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Du Geon Moon
Department of Urology, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea
3 shared publications - Jeong Gu Lee
Department of Urology, Korea University College of Medicine, Seoul, Republic of Korea
3 shared publications Jun Cheon
3 shared publications- Seok Ho Kang
Department of Urology, Korea University Anam Hospital, Korea University Medical Center, Korea University School of Medicine, Seoul, Korea
3 shared publications Hong-Seok Park
2 shared publications- Jun Cheon
Department of Urology, Korea University School of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 15 June 2017
- Published by Springer Nature in BMC Urology
- Vol. 17 (1) , 44
The usefulness of flexible cystoscopy for preventing double-J stent malposition after laparoscopic ureterolithotomy
The aim of this study was to evaluate the role of flexible cystoscopy in preventing malpositioning of the ureteral stent after laparoscopic ureterolithotomy in male patients. From April 2009 to June 2015, 97 male patients with stones >1.8 cm in the upper ureter underwent intracorporeal double-J stenting of the ureter after laparoscopic ureterolithotomy performed by four different surgeons. In the last 50 patients who underwent laparoscopic ureterolithotomy flexible cystoscopy was performed through the urethral route to confirm the position of the double-J stent, while in the first 47 correct positioning of the stent was confirmed through postoperative KUB. The demographic data and perioperative outcomes were reviewed retrospectively. Penalized logistic regression analysis was used to evaluate the effects of flexible cystoscopy. Upward malpositioning of the ureteral stent was found in 9 of the 47 (19.1%) patients who underwent surgery without flexible cystoscopy. Among the 50 most recent patients who underwent surgery with flexible cystoscopy through the urethral route, upward malpositioning was observed in 10 (20%) patients. The factors preventing upward malpositioning of the double-J catheter in multivariate analysis were surgeon (p = 0.039) and use of flexible cystoscopy (p = 0.008). Flexible cystoscopy is a simple, safe, quick, and effective method to identify and correct malpositioning of double-J stents, especially in male patients. This study was registered with ClinicalTrials.gov Registry on May 11, 2017 (retrospective registration) with a trial registration number of NCT03150446 .
- 15 June 2017
- Published by Springer Nature in BMC Urology
- Vol. 17 (1) , 44
Open AccessThe usefulness of flexible cystoscopy for preventing double-J stent malposition after laparoscopic ureterolithotomy
The aim of this study was to evaluate the role of flexible cystoscopy in preventing malpositioning of the ureteral stent after laparoscopic ureterolithotomy in male patients. From April 2009 to June 2015, 97 male patients with stones >1.8 cm in the upper ureter underwent intracorporeal double-J stenting of the ureter after laparoscopic ureterolithotomy performed by four different surgeons. In the last 50 patients who underwent laparoscopic ureterolithotomy flexible cystoscopy was performed through the urethral route to confirm the position of the double-J stent, while in the first 47 correct positioning of the stent was confirmed through postoperative KUB. The demographic data and perioperative outcomes were reviewed retrospectively. Penalized logistic regression analysis was used to evaluate the effects of flexible cystoscopy. Upward malpositioning of the ureteral stent was found in 9 of the 47 (19.1%) patients who underwent surgery without flexible cystoscopy. Among the 50 most recent patients who underwent surgery with flexible cystoscopy through the urethral route, upward malpositioning was observed in 10 (20%) patients. The factors preventing upward malpositioning of the double-J catheter in multivariate analysis were surgeon (p = 0.039) and use of flexible cystoscopy (p = 0.008). Flexible cystoscopy is a simple, safe, quick, and effective method to identify and correct malpositioning of double-J stents, especially in male patients. This study was registered with ClinicalTrials.gov Registry on May 11, 2017 (retrospective registration) with a trial registration number of NCT03150446 .
- Open Access
- 29 August 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 89
Terminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion
Terminal dribbling is one of the lower urinary tract symptoms (LUTS) that has not been widely studied. The aim of this study was to investigate the associations between terminal dribbling (TD) and other parameters such as International Prostate Symptom Score (IPSS) and intravesical prostatic protrusion (IPP). Medical records of male patients with LUTS aged 40 years and older were prospectively collected. Data regarding TD defined by the International Continence Society standardization subcommittee, IPSS, prostate-specific antigen, total prostate volume, and IPP on transrectal ultrasonography were obtained. TD was confirmed by the subsequent uroflowmetry (uroflowmetry-confirmed TD). Logistic regression analysis was performed to identify the parameters affecting TD and uroflowmetry-confirmed TD. Among the 578 men, 226 patients (39.1 %) complained of TD and 157 patients (27.2 %) had objective findings of TD on uroflowmetry. In the logistic regression analysis, IPSS voiding subscore were correlated with TD (Odds ratio 1.06). In addition, IPP was the only significant risk factor for uroflowmetry-confirmed TD (Odds ratio 2.83). Each question of IPSS is not correlated with TD or uroflowmetry-confirmed TD. While the symptom of TD is well correlated with IPSS voiding subscore, objective evidence of TD on uroflowmetry had strong correlation with IPP. TD should be investigated further to reveal its clinical impact and guide a proper management.
- 29 August 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 89
Open AccessTerminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion
Terminal dribbling is one of the lower urinary tract symptoms (LUTS) that has not been widely studied. The aim of this study was to investigate the associations between terminal dribbling (TD) and other parameters such as International Prostate Symptom Score (IPSS) and intravesical prostatic protrusion (IPP). Medical records of male patients with LUTS aged 40 years and older were prospectively collected. Data regarding TD defined by the International Continence Society standardization subcommittee, IPSS, prostate-specific antigen, total prostate volume, and IPP on transrectal ultrasonography were obtained. TD was confirmed by the subsequent uroflowmetry (uroflowmetry-confirmed TD). Logistic regression analysis was performed to identify the parameters affecting TD and uroflowmetry-confirmed TD. Among the 578 men, 226 patients (39.1 %) complained of TD and 157 patients (27.2 %) had objective findings of TD on uroflowmetry. In the logistic regression analysis, IPSS voiding subscore were correlated with TD (Odds ratio 1.06). In addition, IPP was the only significant risk factor for uroflowmetry-confirmed TD (Odds ratio 2.83). Each question of IPSS is not correlated with TD or uroflowmetry-confirmed TD. While the symptom of TD is well correlated with IPSS voiding subscore, objective evidence of TD on uroflowmetry had strong correlation with IPP. TD should be investigated further to reveal its clinical impact and guide a proper management.
- Open Access
- 23 May 2014
- Published by Springer Nature in BMC Urology
- Vol. 14 (1) , 41
Prognostic factors for recurrence-free and overall survival after adrenalectomy for metastatic carcinoma: a retrospective cohort pilot study
The survival benefits of adrenalectomy (ADx) in the setting of metastatic cancer and prognostic factors for recurrence-free (RFS) and overall survival (OS) after adrenalectomy for metastatic carcinoma are still under debate. We evaluated the impact of clinicopathological variables on RFS and OS after ADx for metastatic carcinoma in patients with primary cancer.
- 23 May 2014
- Published by Springer Nature in BMC Urology
- Vol. 14 (1) , 41
Open AccessPrognostic factors for recurrence-free and overall survival after adrenalectomy for metastatic carcinoma: a retrospective cohort pilot study
The survival benefits of adrenalectomy (ADx) in the setting of metastatic cancer and prognostic factors for recurrence-free (RFS) and overall survival (OS) after adrenalectomy for metastatic carcinoma are still under debate. We evaluated the impact of clinicopathological variables on RFS and OS after ADx for metastatic carcinoma in patients with primary cancer.
- 14 December 2012
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 5 (2) , 101-110
Udenafil: efficacy and tolerability in the management of erectile dysfunction
Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil’s efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil’s promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.
- 14 December 2012
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 5 (2) , 101-110
Udenafil: efficacy and tolerability in the management of erectile dysfunction
Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil’s efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil’s promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.
- Open Access
- 1 March 2007
- Published by Medknow in Asian Journal of Andrology
- Vol. 9 (2) , 275-279
Extragastrointestinal stromal tumor presenting as a scrotal mass: an unusual case
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- 1 March 2007
- Published by Medknow in Asian Journal of Andrology
- Vol. 9 (2) , 275-279
Open AccessExtragastrointestinal stromal tumor presenting as a scrotal mass: an unusual case
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- Open Access
- 1 January 2007
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 48 (9) , 956-964
Evaluation of the Quality of Life and the Efficacy of Treatment after High Power Potassium-titanyl-phosphate (KTP) Laser Vaporization for Patients with a Prostate Volume Greater than 40cc
- 1 January 2007
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 48 (9) , 956-964
Open AccessEvaluation of the Quality of Life and the Efficacy of Treatment after High Power Potassium-titanyl-phosphate (KTP) Laser Vaporization for Patients with a Prostate Volume Greater than 40cc
- Open Access
- 1 September 2006
- Published by Medknow in Asian Journal of Andrology
- Vol. 8 (5) , 629-636
Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- 1 September 2006
- Published by Medknow in Asian Journal of Andrology
- Vol. 8 (5) , 629-636
Open AccessTargeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.